- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02954315
The Effect of Almonds on Skin Lipids and Wrinkles
Study Overview
Detailed Description
Primary Endpoint:
A) Change in wrinkle depth. Full facial photographs will be obtained at baseline, 8 weeks, and 16 weeks. The images will be obtained with the 3D Clarity Pro® Facial Modeling and Analysis System (Brigh-Tex BioPhotonics, San Jose, CA) that has standardized positioning and lighting. This system can assess average wrinkle depth. The PI has already validated this measurement tool against standard clinical grading of facial wrinkles[13].
Secondary Endpoint:
A) Change in clinical appearance of facial wrinkles on lateral canthi: Two blinded dermatologists will grade the photographs obtained at each of the time points on the lateral canthi ("crow's feet"). The dermatologists will not know which group the subjects were in.
B) Change in facial sebum production through the use of a Sebumeter, a commonly used device that measures sebum excretion rate [13,17]. Sebum excretion rate will be measured at baseline, 8 weeks, and 16 weeks.
C) Change in serum and sebum lipid profiles obtained through the use of Sebutapes at baseline, 8 weeks, and 16 weeks.
D) Change in the serum and sebum lipid profile for assessment of long chain/short chain fatty acid ratios and the NS ceramide content.
Procedures Involved This study will be a 16-week supplementation study that utilizes two study groups: 1) Control group 2) Almond supplementation: 20% energy intake. This will be a randomized, rater-blinded, controlled study.
There will be a total of 30 subjects:
Control Group: n=15 Almond Supplementation: n=15
The subjects will be recruited from the UC Davis Dermatology Department, the surrounding clinics in a 25 mile radius, and the general population in the Davis and Sacramento areas. The greater Sacramento area has a population of over 2 million to draw from and recruitment will be conducted through the use of Social Media and flyer based recruitment.
Investigators will collect medical history and current medications from study participants- this is outlined in the HIPAA form. The two intervention groups will consist of those receiving almonds and those that are receiving a calorie matched snack. The almond dose will be provided as 20% of total energy (20% E) in the diet. This dose was selected based on a previous randomized trial examining lipid parameters in response to 0, 10%, and 20% E as dietary almonds and a recent meta-analysis of intervention trials of tree nuts [23,24]. The control snack will be a typical western diet snack. The calorie-matched control snack will be commercially available individually wrapped food products such as a small granola bar + pretzels. Once a subject has met inclusion criteria and has signed IRB consent, anthropometric data will be obtained, 3-24 hour recall will be collected by phone, skype, or in person by a Registered Dietitian, training will be provided for recording dietary records, and estimated caloric needs will be calculated. Estimated energy needs (EER) will be determined using the Mifflin-St. Jeor equation and total daily energy needs (TDE) calculated as EER x activity factor of 1.3-1.5 for sedentary to average activity, or a higher activity level as indicated. A representative example of a 60 year old woman, 5'4", 140 pounds with typical activity level yields TDE of approximately 1,600 - 1,800 kcal/day, and 20% E of 320-360 kcal/day. The dose of almonds would be 2 ounces (equal to 23 whole kernels)/day, providing 328 calories.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Sacramento, California, United States, 95816
- UC Davis Department of Dermatology, Clinical Trials Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Postmenopausal women
- Fitzpatrick skin types 1 and 2
- Able to follow dietary intervention and attend all study visits
Exclusion Criteria:
- Those with a nut allergy
Smoking:
- Current smokers
- Those that have smoked within the past year
- Former smokers with greater than a 20 pack-year history of smoking within the past 20 years will be excluded.
- Those with an autoimmune photosensitive condition or a known genetic condition with a deficiency in collagen production (such as Ehler-Danlos)
- Those that already obtain 20% of their energy intake from nut consumption
- Those with implausible reported energy intakes of <1,000 kcal/d or >3,000 kcal/d
- Individuals who are unwilling to discontinue high antioxidant supplements and daily food sources listed below, during the washout and intervention.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Almond arm
The almond dose will be provided as 20% of total energy (20% E) in the diet.
This dose was selected based on a previous randomized trial examining lipid parameters in response to 0, 10%, and 20% E as dietary almonds and a recent meta-analysis of intervention trials.
|
|
|
No Intervention: Western diet Snack (Granola bar + Pretzels)
The control snack will be a typical western diet snack (see Table 1).
The calorie-matched control snack will be commercially available individually wrapped food products such as a small granola bar + pretzels.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in wrinkle depth
Time Frame: 16 weeks
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in clinical appearance of facial wrinkles on lateral canthi
Time Frame: 16 weeks
|
16 weeks
|
|
Change in facial sebum production through the use of a Sebumeter
Time Frame: 16 weeks
|
16 weeks
|
|
Change in serum and sebum lipid profiles
Time Frame: 16 weeks
|
16 weeks
|
|
Change in the serum and sebum lipid profile for assessment of long chain/short chain fatty acid ratios and the NS ceramide content
Time Frame: 16-weeks
|
16-weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Raja K Sivamani, M.D., UC Davis
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 930524
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rhytides
-
AllerganCompletedGlabellar Rhytides | Forehead RhytidesUnited States, Canada, Ireland
-
University of California, DavisCompleted
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar RhytidesUnited States
-
Apyx MedicalCompleted
-
AllerganCompleted
-
Deka Medical, Inc.CompletedWrinkles | RhytidesUnited States
-
Mentor Worldwide, LLCQuintiles, Inc.CompletedGlabellar RhytidesUnited States
-
Sofwave Medical LTDCompletedWrinkle | RhytidesUnited States
-
El. En. SpACompletedWrinkles | RhytidesUnited States
-
Rocky Mountain Biosystems, Inc.Unknown
Clinical Trials on Almonds
-
University of FloridaAlmond Board of CaliforniaCompleted
-
United States Department of Agriculture (USDA)Almond Board of CaliforniaCompleted
-
David BaerAlmond Board of CaliforniaCompletedHealthy | Focus: Effect of Processing on Energy Value of AlmondsUnited States
-
Aga Khan University Hospital, PakistanUniversity of Karachi; PharmEvo Pvt LtdRecruitingVitamin D | Tibia Fractures | Femur Shaft Fracture | Sweet Almonds | Callus Index | Callus BridgingPakistan
-
Boston UniversityTufts UniversityCompletedCoronary Artery DiseaseUnited States
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationCompleted
-
Penn State UniversityAlmond Board of CaliforniaCompleted
-
Tufts UniversityCompletedMild Cognitive ImpairmentUnited States
-
Maastricht University Medical CenterAlmond Board of CaliforniaCompletedPreDiabetes | Overweight and Obesity | Impaired Glucose Tolerance | Impaired Fasting GlucoseNetherlands
-
University of ManitobaAlmond Board of CaliforniaTerminated